Ignite Creation Date:
2025-12-25 @ 3:29 AM
Ignite Modification Date:
2026-03-08 @ 3:39 AM
Study NCT ID:
NCT04111705
Status:
COMPLETED
Last Update Posted:
2025-04-01
First Post:
2019-08-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer
Sponsor:
Intergroupe Francophone de Cancerologie Thoracique
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-08-05
Start Date Type:
ACTUAL
Primary Completion Date:
2022-08-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-12-15
Completion Date Type:
ACTUAL
First Submit Date:
2019-08-30
First Submit QC Date:
None
Study First Post Date:
2019-10-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-03-26
Last Update Post Date:
2025-04-01
Last Update Post Date Type:
ACTUAL